Clinical Trials Logo

Clinical Trial Summary

This is a biomarker multi-centre study to validate an extraction method of fungal and bacterial DNA extracted from vaginal swabs from adult women with confirmed VVC. The study population will consist of post-menarchal, pre-menopausal females, 18 years or older, seeking care for VVC symptoms. Vaginal samples will be examined under a microscope for yeast forms (hyphae or pseudohyphae) or budding yeast. If the Investigator assesses that the patient has VVC, based on examination and the potassium hydroxide (KOH) test, two vaginal secretion samples will be collected by a vaginal swab. One sample will be cultured to verify the presence of Candida and the other will be used for sequencing analysis of the vaginal microbiome. Samples from a total of 10 women are planned to be taken.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05327192
Study type Observational
Source Gedea Biotech AB
Contact
Status Completed
Phase
Start date May 12, 2022
Completion date July 6, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05012852 - Evaluation of VagiVitalAC for Treatment of Candida Vulvovaginitis N/A
Completed NCT02150655 - Study of the Microbiota, Metabolome, and Environmental Toxins in Relation to Reproductive Health in Rwandan Women Phase 0
Completed NCT00755053 - Comparative Efficacy of Ovule vs Tablet Phase 3
Completed NCT02679456 - Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis Phase 2
Completed NCT02242695 - Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis Phase 4
Not yet recruiting NCT05079711 - Comparative Performance of a Vaginal Yeast Test
Completed NCT00895453 - Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC) N/A
Completed NCT05399641 - Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis Phase 3
Completed NCT01806623 - The Study Of Fluconazole For Vulvovaginal Candidiasis Phase 3
Completed NCT05507333 - Clinical Performance of the Gedea Pessary in Adult Women With Vulvovaginal Candidiasis N/A
Completed NCT01144286 - Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment Phase 2
Completed NCT00353561 - Diabetes Mellitus and Vulvovaginal Candidiasis Phase 3
Recruiting NCT05895162 - Zinc-containing Vaginal Gel and Oral Fluconazole for Vulvovaginal Candidiasis. N/A
Recruiting NCT05908682 - Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes
Completed NCT02203942 - Comparing NAAT Testing to Standard Methods for the Diagnosis of Vaginitis N/A
Completed NCT01926028 - Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis Phase 1/Phase 2
Completed NCT00194324 - Effect of Exercise on Spread of the Miconozole Nitrate OVULE in the Vagina Phase 4
Completed NCT02866227 - TOL-463 Phase 2 Study for Vaginitis Phase 2
Withdrawn NCT05031481 - Efficacy and Safety of Different Doses of Venus Association in Patients With Vulvovaginal Candidiasis. Phase 2
Completed NCT03761628 - Clinical Performance of a Vaginal Pessary (pHyph) in Vulvovaginal Candidiasis N/A